Intercept Pharma (ICPT) Tops Q1 EPS by 64c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Intercept Pharmaceuticals (ICPT) PT Raised to $223 at BMO Capital; 'Ocaliva Off to a Strong Start'
May 5, 2017 7:25 AM EDTBMO Capital raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $223.00 (from $221.00) while maintaining a Outperform rating with Ocaliva off to a strong start.
Analyst M. Ian Somaiya is raising Ocaliva estimates in 2017 and beyond based on steady demand in... More
